Business ❯ Finance

Pharmaceutical Industry

Market Trends Stock Market Drug Pricing Drug Manufacturers Drug Development Company Performance Market Competition Market Reactions Market Dynamics Market Practices Vaccine Development Lobbying Sun Pharmaceutical Industries Drug Approvals Pharmaceutical Companies Drug Costs Drug Companies Market Impact Indian Pharma Exporters Stock Performance Packaging Industry Sarepta Therapeutics Company Earnings Mergers and Acquisitions Pharmaceutical Stocks Manufacturing Stock Market Performance Pricing Strategies Research and Development Company News Market Protection Clinical Trials Clinical Development Corporate Governance Corporate Restructuring Financial Reporting Drug Licensing Market Response Drug Trials Company Analysis Market Launch

FDA Approves Juvmo as First D1/D5 Agonist for Parkinson’s Disease

The drug’s D1/D5 mechanism could slow patients’ need to raise levodopa doses, with U.S. availability scheduled for October 2026.

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

Pfizer CFO Dave Denton to Exit and Cecile Guegan Named Interim

FDA Grants Accelerated Approval to Kresladi, First Gene Therapy for Severe Pediatric LAD-1

EU Seals Provisional Overhaul of Drug Rules to Speed Access and Spur Innovation

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

Pfizer–Trump Drug-Pricing Deal and ‘TrumpRx’ Plan Jolt Health-Care Stocks Higher

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure